Neoadjuvant Database
NCT04031612 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2019-07-24
Summary
The NEOADJ Database base contains data collected during the regular clinical patient management (sociodemographic, clinical, pathological, radiological, biological, disease evolution...). This database allows easy access to information in a centralized and structured way.
This cohort is used to gather insights for research purposes. All data collected come from medical files of patients managed at Centre Georges Francois Leclerc, Dijon, France.
Conditions
- Neoadjuvant Treatment in Breast Cancer
Interventions
- DRUG
-
Neoadjuvant therapy
Neoadjuvant therapy
Sponsors & Collaborators
-
Centre Georges Francois Leclerc
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-09-09
- Primary Completion
- 2024-09-30
- Completion
- 2024-09-30
Countries
- France
Study Locations
More Related Trials
-
Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients
NCT06631066 ·Status: COMPLETED ·Phase: NA
-
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
NCT00432172 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
NCT01564056 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
NeoRad Breast Cancer Study
NCT04261244 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
NCT01565499 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
NCT02339532 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
NCT01815242 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00343512 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT00461344 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
NCT01352494 ·Status: UNKNOWN ·Phase: PHASE2
-
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
NCT06931769 ·Status: RECRUITING
-
Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers
NCT01367288 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
NCT04224922 ·Status: COMPLETED ·Phase: PHASE2
-
Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy
NCT04504747 ·Status: RECRUITING
-
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
NCT06155305 ·Status: RECRUITING
-
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
NCT02124902 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
NCT06040593 ·Status: COMPLETED
-
Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
NCT01625429 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients
NCT05755581 ·Status: UNKNOWN ·Phase: PHASE1
-
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
NCT05731258 ·Status: RECRUITING
-
Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy
NCT07260188 ·Status: RECRUITING
-
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
NCT02689921 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
NCT00256243 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04126525 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
NCT00006120 ·Status: UNKNOWN ·Phase: PHASE2